HC Wainwright Issues Optimistic Estimate for Harrow Earnings

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at HC Wainwright upped their Q4 2024 earnings estimates for shares of Harrow in a research report issued on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.16 per share for the quarter, up from their previous forecast of ($0.07). HC Wainwright currently has a “Buy” rating and a $57.00 target price on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Harrow’s Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.07 EPS and FY2025 earnings at $0.21 EPS.

Separately, B. Riley reduced their target price on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th.

Harrow Price Performance

NASDAQ HROW opened at $28.09 on Friday. Harrow has a 52 week low of $9.86 and a 52 week high of $59.23. The firm has a market capitalization of $1.00 billion, a P/E ratio of -29.88 and a beta of 0.69. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The company has a 50-day moving average price of $29.67 and a 200-day moving average price of $38.48.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently added to or reduced their stakes in HROW. Principal Financial Group Inc. purchased a new stake in Harrow during the 3rd quarter valued at approximately $329,000. Quest Partners LLC purchased a new stake in Harrow during the 3rd quarter valued at approximately $29,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Harrow during the 3rd quarter valued at approximately $5,864,000. Intech Investment Management LLC purchased a new stake in Harrow during the 3rd quarter valued at approximately $460,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after buying an additional 166,602 shares in the last quarter. 72.76% of the stock is owned by hedge funds and other institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.